Auxogyn, Inc. announced that they have signed a strategic partnership with the Valencia Infertility Institute (IVI). The Valencia Infertility Institute, with its 23 clinics all over the world, is a global leader in reproductive medicine. Under the terms of the agreement, Auxogyn will put in its Early Embryo Viability Assessment (Eeva) systems in various IVI clinics to support two Auxogyn research initiatives. The Auxogyn-IVI partnership will also maintain Auxogyn's current aneuploidy, also known as "an abnormal number of chromosomes", research program.

"Auxogyn is very pleased to collaborate with IVI, which has one of the world's largest networks of IVF clinics and a proven track record of promoting clinical and scientific progress through cutting-edge research," said Lissa Goldenstein, President and CEO of Auxogyn. "Through this partnership, we're accelerating our growth in Europe and advancing our mission of improving outcomes for patients undergoing IVF."

"IVI prides itself on leveraging new approaches to offer patients the latest treatment options to achieve the best results," commented Dr. Antonio Pellicer, founder of IVI. "We look forward to partnering with Auxogyn on important research that offers new hope to our patients and advances the reproductive medicine field."